Jörg Hinrich Wischhusen - Gynecology

Author Information

Jörg Hinrich Wischhusen is currently affiliated with the Department of Gynecology at the University Hospital Würzburg in Würzburg, Germany. His research spans various facets of immunology, neurodegeneration, and oncology, with a significant focus on the molecular mechanisms underlying immune responses and disease progression.

Research Contributions

Jörg Hinrich Wischhusen has made substantial contributions to the fields of immunology and oncology. His work includes exploring the roles of growth differentiation factors and immune checkpoint inhibitors in tumor microenvironments. Noteworthy studies include the investigation of GDF-15 as a biomarker and its implications in immune checkpoint resistance, as well as the development of novel immunoassays for detecting SARS-CoV-2 antibodies. His research is pivotal for advancing the understanding of tumor-immune interactions and developing potential therapeutic strategies.

Aliases

Jörg Hinrich Wischhusen is also known by several aliases, including Jörg Wischhusen, Jörg Wischhusen, J Wischhusen, J. Wischhusen, and Jorg Wischhusen.

Publication and Citation Metrics

Total Papers	122
Total Citations	8090
h-index	47

Publications:

Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice

DOI: 10.1016/j.bbi.2022.01.007

Year: 2022

504 A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

DOI: 10.1136/jitc-2021-sitc2021.504

Year: 2021

Performance of Three SARS-CoV-2 Immunoassays, Three Rapid Lateral Flow Tests, and a Novel Bead-Based Affinity Surrogate Test for the Detection of SARS-CoV-2 Antibodies in Human Serum

DOI: 10.1128/JCM.00319-21

Year: 2021

Performance of three SARS-CoV-2 immunoassays, three rapid lateral flow tests and a novel bead-based affinity surrogate test for the detection of SARS-CoV-2 antibodies in human serum

DOI: 10.1101/2021.02.07.21251062

Year: 2021

Tumor-derived GDF-15 to suppress t-lymphocyte recruitment to the tumor microenvironment resulting in resistance to ANTI-PD-1 treatment.

DOI: 10.1200/JCO.2021.39.15_SUPPL.E14532

Year: 2021

568 Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment

DOI: 10.1136/jitc-2021-sitc2021.568

Year: 2021

Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint

DOI: 10.3389/fimmu.2020.00951

Year: 2020

Growth differentiation factor 15 is increased in stable MS

DOI: 10.1212/nxi.0000000000000675

Year: 2020

Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer

DOI: 10.1136/jitc-2020-000676

Year: 2020

Abstract 5597: Tumor-derived GDF-15 suppresses T-lymphocyte recruitment to the tumor microenvironment

DOI: 10.1158/1538-7445.am2020-5597

Year: 2020

Can Polyhydramnios Be Prevented?

What Tests Might Be Conducted?

Why is Patient Mobility Important in Gynecology?

What is Jojoba Oil?

What is Misoprostol?

How are Pregnancy Hormones Measured?

What are Immunological Techniques?

Why are Ureteral Stents Used in Gynecology?

Who are the Ideal Candidates for ZIFT?

Are Strawberries Beneficial During Pregnancy?

Partnered Content Networks

Relevant Topics